CDKN2A and neoplasm: Patients with p16-positive OSCC had a significantly better overall survival rate than those with p16-negative tumours with a 5-year overall survival probability of 78 vs 43% (hazard ratio=0.414; 95% CI=0.187–0.915; P=0.0244).